Despite their usefulness, linear models in GBAS have limitations. They may oversimplify the biological mechanisms involved, ignoring factors like metabolism, bioavailability, and non-linear responses at various doses. Furthermore, they often fail to account for threshold effects or saturation points where increases in dose do not lead to proportional increases in effect. This can lead to inaccurate risk assessments if used in isolation.
